Fifth Third Bancorp lessened its holdings in shares of CVS Health Co. (NYSE:CVS - Free Report) by 8.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 162,339 shares of the pharmacy operator's stock after selling 14,719 shares during the quarter. Fifth Third Bancorp's holdings in CVS Health were worth $7,287,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of CVS. Assetmark Inc. increased its position in shares of CVS Health by 9.7% during the 3rd quarter. Assetmark Inc. now owns 410,001 shares of the pharmacy operator's stock valued at $25,781,000 after purchasing an additional 36,132 shares during the period. TD Private Client Wealth LLC grew its holdings in CVS Health by 28.7% during the third quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator's stock worth $2,951,000 after acquiring an additional 10,465 shares during the period. Cullinan Associates Inc. raised its position in CVS Health by 43.8% in the third quarter. Cullinan Associates Inc. now owns 122,682 shares of the pharmacy operator's stock worth $7,125,000 after acquiring an additional 37,395 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of CVS Health by 4.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator's stock valued at $90,200,000 after purchasing an additional 66,244 shares in the last quarter. Finally, Sompo Asset Management Co. Ltd. grew its stake in shares of CVS Health by 8.4% in the 3rd quarter. Sompo Asset Management Co. Ltd. now owns 134,523 shares of the pharmacy operator's stock worth $8,459,000 after purchasing an additional 10,453 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.
CVS has been the subject of a number of research reports. Mizuho reduced their target price on shares of CVS Health from $73.00 to $66.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. TD Cowen lifted their target price on CVS Health from $73.00 to $80.00 and gave the stock a "buy" rating in a report on Monday, November 25th. UBS Group upped their target price on CVS Health from $60.00 to $62.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Barclays dropped their price target on CVS Health from $75.00 to $71.00 and set an "overweight" rating on the stock in a research note on Thursday, November 7th. Finally, Deutsche Bank Aktiengesellschaft raised shares of CVS Health from a "hold" rating to a "buy" rating and set a $66.00 price objective for the company in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, CVS Health currently has a consensus rating of "Moderate Buy" and a consensus target price of $68.71.
Get Our Latest Report on CVS Health
Shares of NYSE CVS opened at $54.71 on Monday. CVS Health Co. has a one year low of $43.56 and a one year high of $80.75. The business's 50-day moving average price is $51.24 and its two-hundred day moving average price is $56.21. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. The company has a market capitalization of $68.84 billion, a P/E ratio of 13.88, a price-to-earnings-growth ratio of 0.80 and a beta of 0.59.
CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.01. The firm had revenue of $95.43 billion for the quarter, compared to analyst estimates of $92.72 billion. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The company's revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.21 earnings per share. Analysts anticipate that CVS Health Co. will post 5.22 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd will be given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.86%. The ex-dividend date is Thursday, January 23rd. CVS Health's payout ratio is 67.51%.
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.